ZFIN ID: ZDB-PUB-160531-4
Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds
Bruni, G., Rennekamp, A.J., Velenich, A., McCarroll, M., Gendelev, L., Fertsch, E., Taylor, J., Lakhani, P., Lensen, D., Evron, T., Lorello, P.J., Huang, X.P., Kolczewski, S., Carey, G., Caldarone, B.J., Prinssen, E., Roth, B.L., Keiser, M.J., Peterson, R.T., Kokel, D.
Date: 2016
Source: Nature Chemical Biology   12(7): 559-66 (Journal)
Registered Authors: McCarroll, Matthew N., Peterson, Randall
Keywords: Chemical biology, Drug discovery, Molecular neuroscience, Phenotypic screening
MeSH Terms:
  • Animals
  • Antipsychotic Agents/analysis*
  • Antipsychotic Agents/chemistry
  • Antipsychotic Agents/pharmacology*
  • Behavior, Animal/drug effects*
  • Larva/drug effects
  • Mice
  • Molecular Structure
  • Zebrafish*/growth & development
PubMed: 27239787 Full text @ Nat. Chem. Biol.
Many psychiatric drugs act on multiple targets and therefore require screening assays that encompass a wide target space. With sufficiently rich phenotyping and a large sampling of compounds, it should be possible to identify compounds with desired mechanisms of action on the basis of behavioral profiles alone. Although zebrafish (Danio rerio) behavior has been used to rapidly identify neuroactive compounds, it is not clear what types of behavioral assays would be necessary to identify multitarget compounds such as antipsychotics. Here we developed a battery of behavioral assays in larval zebrafish to determine whether behavioral profiles can provide sufficient phenotypic resolution to identify and classify psychiatric drugs. Using the antipsychotic drug haloperidol as a test case, we found that behavioral profiles of haloperidol-treated zebrafish could be used to identify previously uncharacterized compounds with desired antipsychotic-like activities and multitarget mechanisms of action.